Saved in:
Bibliographic Details
Main Authors: Li, Kaiqiang, Liu, Yuanjie, Zhang, Chen, Yu, Huahua, Liu, Song, Xing, Ronge, Li, Pengcheng, Li, Rongfeng
Format: Artículo científico
Language:en
Published: Carbohydrate research 2026
Subjects:
Online Access:https://pubmed.ncbi.nlm.nih.gov/41921298/
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Enzymatic depolymerization, structural characterization, and anticoagulant activity evaluation of chondroitin sulfate A oligosaccharides. Li, Kaiqiang Liu, Yuanjie Zhang, Chen Yu, Huahua Liu, Song Xing, Ronge Li, Pengcheng Li, Rongfeng Anticoagulants Chondroitin Sulfates Oligosaccharides Polymerization Humans Hyaluronoglucosaminidase Blood Coagulation Partial Thromboplastin Time Structure-Activity Relationship Chondroitin sulfate (CS) polysaccharides exhibit intrinsic structural heterogeneity, limiting precise studies of their bioactivities and therapeutic applications. To obtain homogeneous CS oligosaccharides and elucidate structure-activity relationships, we developed a controlled enzymatic method for preparing well-defined chondroitin sulfate A (CSA) oligosaccharides and investigated their chain length-dependent anticoagulant mechanisms. Herein, hyaluronidase was used to depolymerize CSA and subsequently purified by sequential ultrafiltration and anion-exchange chromatography, yielding CSA oligosaccharide fractions (CSA4, CSA6, CSA8, CSA10 and CSA12). Their structures were confirmed by NMR spectroscopy and mass spectrometry. In vitro anticoagulation assays showed significant chain-length dependence: longer oligomers (CSA8, CSA10 and CSA12) profoundly prolonged activated partial thromboplastin time (APTT) and thrombin time (TT), suggesting potentiation of endogenous serine protease inhibitors. However, shorter oligomers (CSA4 and CSA6) just selectively prolonged prothrombin time (PT), indicating extrinsic pathway modulation. This work provides a reliable method for preparing CSA oligosaccharides and establishes a molecular foundation for developing safer, predictable CS-based anticoagulants.